Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shree Ganesh Biotech (India)'s annualized net income for the quarter that ended in Mar. 2026 was ₹-5.97 Mil. Shree Ganesh Biotech (India)'s average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹636.33 Mil. Therefore, Shree Ganesh Biotech (India)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -0.94%.
The historical rank and industry rank for Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity or its related term are showing as below:
BOM:539470'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.41 Med: 2.16 Max: 30.92
Current: 0.81
During the past 12 years, Shree Ganesh Biotech (India)'s highest Return-on-Tangible-Equity was 30.92%. The lowest was 0.41%. And the median was 2.16%.
BOM:539470's Return-on-Tangible-Equity is ranked worse than 74.7% of 249
companies
in the Agriculture industry
Industry Median: 7.18
vs BOM:539470: 0.81
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shree Ganesh Biotech (India) Return-on-Tangible-Equity Related Terms
Shree Ganesh Biotech (India) Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539470 vs CTVA, CF, MOS: Return-on-Tangible-Equity Comparison
For the Agricultural Inputs subindustry, Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Ganesh Biotech (India) Return-on-Tangible-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -0.94% mean?
Shree Ganesh Biotech (India) (BOM:539470) has a Return-on-Tangible-Equity of -0.94% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shree Ganesh Biotech (India) and its competitors. Over the past decade, Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity has ranged from 0.41 to 30.92. According to the industry distribution chart, Shree Ganesh Biotech (India) ranks #186 out of 249 companies in the Agriculture industry, placing it in the top 74.7%.
Is Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity too high?
Shree Ganesh Biotech (India)'s current Return-on-Tangible-Equity is -0.94%. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 30.92. Based on the distribution chart, Shree Ganesh Biotech (India) ranks #186 out of 249 companies in the Agriculture industry, which is below the industry midpoint. Overall, Shree Ganesh Biotech (India) has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shree Ganesh Biotech (India)'s Return-on-Tangible-Equity compare to CTVA and CF?
According to the Agriculture industry distribution chart, Shree Ganesh Biotech (India) ranks #186 out of 249 companies for Return-on-Tangible-Equity. This places Shree Ganesh Biotech (India) in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.18. Historically, Shree Ganesh Biotech (India)'s own Return-on-Tangible-Equity has ranged from 0.41 to 30.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for an Agriculture company?
The median Return-on-Tangible-Equity among Agriculture companies is 7.18, based on 249 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shree Ganesh Biotech (India) and its competitors. For the Agriculture industry, the median Return-on-Tangible-Equity is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Ganesh Biotech (India)'s current Return-on-Tangible-Equity is -0.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Ganesh Biotech (India) stock overvalued right now?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) (BOM:539470) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹0.19, compared to a current price of ₹0.54 — trading 184.2% above its estimated fair value. The current Return-on-Tangible-Equity is -0.94%. Shree Ganesh Biotech (India)'s overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shree Ganesh Biotech (India) (BOM:539470), the current Return-on-Tangible-Equity is -0.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Ganesh Biotech (India) (BOM:539470) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Ganesh Biotech (India) stock appears to be overvalued.
The current stock price of ₹0.54 is trading 184.2% above its estimated GF Value™ of ₹0.19.
GuruFocus considers Shree Ganesh Biotech (India) to be Significantly Overvalued.
Key valuation signals for BOM:539470:
Return-on-Tangible-Equity: -0.94%
GF Value™: ₹0.19 vs. price of ₹0.54 (184.2% above fair value)
No single metric tells the full story. See the BOM:539470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Ganesh Biotech (India) Ltd is an India-based company mainly engaged in the business of production, processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc.
43GF Score
Get the complete analysis for BOM:539470
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539470 has been successfully added to your 
